Atara Biotherapeutics Transfers Tabelecleucel Development to Pierre Fabre Pharmaceuticals for EBV+ PTLD Treatment

Atara Biotherapeutics Transfers Tabelecleucel Development to Pierre Fabre Pharmaceuticals

Atara Biotherapeutics Inc. has officially transferred the Biologics License Application (BLA) for tabelecleucel, an innovative allogeneic T-cell therapy, to Pierre Fabre Pharmaceuticals Inc. This significant move highlights the urgency and potential of tabelecleucel in addressing Epstein-Barr virus-positive post-transplant lymphoproliferative disorder (EBV+ PTLD), a rare and serious condition that can arise after hematopoietic cell or solid organ transplants. Currently, the BLA is under U.S. Food and Drug Administration (FDA) Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date set for January 10, 2026. This timeline underscores the commitment of both companies to expedite the development of a treatment that offers hope to patients who often face grim prognoses.

Tabelecleucel represents a breakthrough in targeted therapies for EBV+ PTLD, a malignancy that stems from diminished T-cell activity due to immunosuppression post-transplant. The therapy’s design as an off-the-shelf, EBV-specific T-cell immunotherapy aims to directly target and eliminate EBV-infected cells. Clinical data supporting its efficacy comes from studies involving over 430 patients, including the ongoing pivotal ALLELE study. The BLA was resubmitted on July 11, 2025, and received FDA acceptance for review just days later, reinforcing the urgency of this treatment for patients with limited options. Adriana Herrera, CEO of Pierre Fabre, emphasizes that this transfer marks a pivotal milestone in making this therapy available to those in critical need.

The collaboration between Atara Biotherapeutics and Pierre Fabre represents a strategic shift aimed at enhancing the therapeutic landscape for EBV+ PTLD. While Atara Biotherapeutics remains focused on its core operations, the transfer allows for dedicated resources and expertise from Pierre Fabre to drive the clinical and commercial development of tabelecleucel. The ongoing collaboration with the FDA is crucial to ensuring a thorough review process, as both companies share a commitment to improving patient outcomes in a challenging therapeutic area.

In related news, the ongoing efforts to address EBV+ PTLD reflect a broader trend in biotechnology towards precision medicine, where targeted therapies are developed to meet the unique needs of specific patient populations. As the landscape of immunotherapy continues to evolve, the successful development of tabelecleucel could set a precedent for future treatments for other rare malignancies linked to viral infections.